Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 41 of 41

Filter Applied: adverse drug reaction (Click to remove)

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023

Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023

A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022

Sweet Syndrome
Stat Pearls www.ncbi.nlm.gov, Sept, Goyal,V.P. & Holmes,H, 2022

Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021

Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021

Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021

Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Toxic Diffuse Isolated Cerebellar Edema from Over-the-Counter Health Supplements
Neurol 92:965-966, Kim, D.D.,et al, 2019

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018

Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018

Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018

Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018

Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018

Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma
Case Rep Neurol Med 2018;doi:10.1155/2018/2548528, Shah, S.,et al, 2018

Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018

Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Eur J Cancer 54:139-148, Michot, JM,.,et al, 2016

Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016

Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016

A 35-Year-Old Man with 2 Episodes of Meningoencephalitis Associated with Flu-Like Illness
Neurol 84:e60-e64, Lewis, S.L., 2015

Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015

Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Pseudotumor Cerebri
Adams & Victors Principles of Neurology, Chp 30, pg 628, Ropper, A.H.,et al, 2014

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Mailuoning for Acute Ischemic Stroke
Stroke 41:e443-e444, Weimin,Y.,et al, 2010

Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009

Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008

Carbamazepine Encephalopathy Masquerading as Creutzfeldt-Jakob Disease
Neurol 65:650-651, Horvath,J.,et al, 2005

The Need for Regulation of Dietary Supplements-Lessons From Ephedra
JAMA 289:1568-1570, 1537, Fontanarosa,P.B.,et al, 2003

Dietary Supplements Containing Ephedra Alkalokds
NEJM 344:1095-1097, Hutchins,G.M.,et al, 2001

Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids
NEJM 343:1833-1838,1886, Haller,C.A. & Benowitz,N.L., 2000

Protein C Deficiency Related to Valproic Acid Therapy: A Possible Association with Childhood Stroke
J Pediatr 137:714-718, Gruppo,R.,et al, 2000

Butyrolactone-Induced Central Nervous System Depression After Ingention of RenewTrient, a"Dietary Supplement"
NEJM 339:847-848, LoVecchio,F.,et al, 1998

Chloroquine Myopathy and Neuropathy with Elevated CSF Protein
Neurol 51:1226-1227, Wasay,M.,et al, 1998

Treatment of Myasthenia Gravis by Immunoadsorption of Plasma
Neurol 45:338-344, Grob,D.,et al, 1995

Bovine Gangliosides and Acute Motor Polyneuropathy
BMJ 305:1330-1331, Figueras,A.,et al, 1992

Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991

Ibuprofen-Induced Meningitis:Detection of Intrathecal IgG Synthesis & Immune Complexes
Neurol 39:1578-1580, Chez,M.,et al, 1989



Showing articles 0 to 41 of 41